D
URING 1958 and 1959 at Northwestern Universitv (Chicago). we developed transplantation of the canine liver alone. I parallel to similar independent investigations in Boston hy Francis Moore.:'" The liver also was transplanted as a component of abdominal multivisceral grafts. 4 At the beginning. these were technical and physiologic exercises. because long-term survival of an organ allograft had never been achieved in any species.
The possibility of clinically exploiting transplantation brightened. however. between January 1959 and the date of our first human liver replacement in March 1963. During this 4-year period. Joseph Murray in Boston 5 -7 and the French teams of Jean HamburgerH and Rene Kuss" produced the 7 examples shown in Table 1 of survival exceeding 6 months following human kidney transplantation. All of the patients except the last one had received total body irradiation, and in addition, 4 of the 5 French patients were treated with unstipulated doses of adrenal cortical steroids (Table 1) whose weak anti rejection effect had been demonstrated by Billingham. Krohn. and Medawar lO in a rabbit skin graft model. The seventh recipient was treated with the 6-mercaptopurine derivative (6-MP). azathioprine. Bob Schwartz's gift to transplantation. II . 12 It had been recognized during 1959 to 1962 that total hody irradiation would permit successful renal transplantation in only a small percent of cases. Consequently. the option of immunosuppression with 6-MP or its derivative, azathioprine was greeted initially with feverish enthusiasm. However. the preclinical studies of the new drugs by Calne13·I~ and Zukoski.15 as well as Murray's human triaI5,-7 cautioned that the clinical results might not he substantially better than with irradiation. even when azathioprine was combined with other cytotoxic agents. The seventh patient in Table 1 was the only recipient of the first 10 treated in Boston with 6-MP (n = 2) or azathioprine (n = 8) whose kidney allograft eventually survived more than 6 months. At the nadir of the resulting pessimism. we made our most important contribution to transplantation. 16 Realizing that clinical liver transplantation could never he attempted without first succeeding with the simpler renal procedure. we had turned our laboratory research to the canine kidney transplant model at the University of Colorado (where I had moved in November. 1961). Two reproducible observations were made. first in the mongrel dogs, and then in humans, that came to dominate future developments in organ transplantation.
First, rejection. which had been considered to be one of nature's strongest and most irrevocable reaction. could he readily reversed hy adding high doses of prednisone to recipients under primary immunosuppression with azathioprine. Second. successfully treated recipients appeared to develop donor specific tolerance. This was manifested by the ability later on to wean the doses of drugs to levels below those which had failed at the outset to prevent the onset of rejection.
Using azathioprine plus dose maneuverable prednisone. we began our clinical kidney transplant service in the autumn of 1962 at about the same time as David Hume. who was informed on a day to day hasis of our research and clinical findings. initiated his program at the Medical College of Virginia (Richmond)n Nine of the first 10 recipients of live donor kidney allografts had prolonged graft survival. 16 including two who bear the longest continuously functioning allografts in the world today (>35.5 years The early kidney experience triggered our attempts beginning in March of 1963 to replace the liver. the first extrarenal organ to be transplanted in humans. After the first three reported patients. Figure I with their doctor. Carl Groth from the Karolinska Institute. then an NIH fellow in Denver. and now the President elect of the Transplantation Society. Another child from that early era whose operation was in January, 1970. is the longest surviving liver recipient in the world, married and in perfect health today.
The successful liver transplantations in the summer of 1967 expanded the horizon of transplantation from the kidney to all of the vital extrarenal organs. Within the succeeding 12 months. long survival was accomplished in other centers using variations of the same immunosuppres- sion for heart, lung, and pancreas recipients. Another decade would pass, however. before the advent of cyc1ospo-rine23.~4 would make transplantation of the liver 25 or other cadaver organs a reliahle service. Tacrolimus. the first immunosuppressant to be evaluated primarily with liver transplantation. 2 " has allowed further improved survival of all transplanted organs induding the intestine.
In later years. the management strategy originally developed with azathioprine and prednisone ( Table 2) accommodated more potent haseline drugs as these came along (i.e., cydosporine and tacrolimus in place of azathioprine) and adjunct agents (e.g .. ALG and increasingly selective antilymphoid antibody preparations, mycophenolate mofetil. and other second line drugs). Despite the failure to understand what was being accomplished, the easily taught The treatment regimens were shown ~ decades later to have been effective hecause they fostered chimerism-dependent tolerance mechanisms 2 -:'.2s which were the same as in the neonatal models of Billingham. Brent. and Medawar?"
The liver. which is more toler~genic than other organs. 30 . 31 ullimately became the key organ in solving the immunologic mystery of allograft acceptance and acquired tolerance. 27 . 2H
